Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies

[1]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Luini,et al.  Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Katalinic,et al.  Epidemiology of Breast Cancer - Current Figures and Trends. , 2013, Geburtshilfe und Frauenheilkunde.

[4]  P. Fasching,et al.  Advances in Breast Cancer - Looking Back over the Year. , 2012, Geburtshilfe und Frauenheilkunde.

[5]  P. V. van Diest,et al.  Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases , 2012, Cancer.

[6]  P. Fasching,et al.  Biomarkers in Breast Cancer - An Update. , 2012, Geburtshilfe und Frauenheilkunde.

[7]  Shou‐Tung Chen,et al.  Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients , 2012, Journal of breast cancer.

[8]  D. Edwards,et al.  The biology of progesterone receptor in the normal mammary gland and in breast cancer , 2012, Molecular and Cellular Endocrinology.

[9]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[11]  M. Beckmann,et al.  Invasive Breast Cancer: Recognition of Molecular Subtypes , 2011, Breast Care.

[12]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[13]  Pieter Wesseling,et al.  Receptor conversion in distant breast cancer metastases , 2010, Breast Cancer Research.

[14]  J. Visvader,et al.  Control of mammary stem cell function by steroid hormone signalling , 2010, Nature.

[15]  C. Clarke,et al.  Progesterone induces adult mammary stem cell expansion , 2010, Nature.

[16]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Brisken,et al.  Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland , 2010, Proceedings of the National Academy of Sciences.

[18]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Graham,et al.  DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. , 2009, Endocrinology.

[20]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Brisken,et al.  Alveolar and Lactogenic Differentiation , 2006, Journal of Mammary Gland Biology and Neoplasia.

[22]  Guoqing Diao,et al.  Estimation of time‐dependent area under the ROC curve for long‐term risk prediction , 2006, Statistics in medicine.

[23]  J. Cuzick,et al.  Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Lange,et al.  Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. , 2005, Molecular endocrinology.

[25]  C. Osborne,et al.  Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Kittrell,et al.  Hormone dependence in premalignant mammary progression. , 2003, Cancer research.

[27]  J. Li,et al.  A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. , 2002, Molecular endocrinology.

[28]  E. Anderson.  Progesterone receptors – animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis , 2002, Breast Cancer Research.

[29]  F. Kittrell,et al.  Biological and genetic properties of the p53 null preneoplastic mammary epithelium , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  G. Shyamala,et al.  Cellular expression of estrogen and progesterone receptors in mammary glands: regulation by hormones, development and aging , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[31]  J. Sloane,et al.  Abnormal regulation of the oestrogen receptor in benign breast lesions , 2000, Journal of clinical pathology.

[32]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[33]  K. Horwitz,et al.  Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.

[34]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[35]  D. G. Altman,et al.  Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.

[36]  F. Harrell,et al.  Regression models in clinical studies: determining relationships between predictors and response. , 1988, Journal of the National Cancer Institute.

[37]  S. Leung,et al.  Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients , 2009, Breast Cancer Research and Treatment.

[38]  R. Sutherland,et al.  Estrogen and Progestin Regulation of Cell Cycle Progression , 2004, Journal of Mammary Gland Biology and Neoplasia.

[39]  Cathrin Brisken,et al.  Hormonal Control of Alveolar Development and Its Implications for Breast Carcinogenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[40]  J. Rosen.  Hormone receptor patterning plays a critical role in normal lobuloalveolar development and breast cancer progression. , 2003, Breast disease.

[41]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[42]  Ørnulf Borgan,et al.  A method for checking regression models in survival analysis based on the risk score , 1996, Lifetime data analysis.

[43]  M Schumacher,et al.  A bootstrap resampling procedure for model building: application to the Cox regression model. , 1992, Statistics in medicine.